These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15783248)

  • 1. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD
    Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
    Rackoff PJ; Sebba A
    Treat Endocrinol; 2005; 4(4):245-51. PubMed ID: 16053341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: new indications and methods of administration.
    Reid IR
    Curr Opin Rheumatol; 2003 Jul; 15(4):458-63. PubMed ID: 12819475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates.
    Lambrinoudaki I; Christodoulakos G; Botsis D
    Ann N Y Acad Sci; 2006 Dec; 1092():397-402. PubMed ID: 17308164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of highly potent bisphosphonates in the treatment of osteoporosis.
    McClung M
    Curr Osteoporos Rep; 2003 Dec; 1(3):116-22. PubMed ID: 16036074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for the prevention and treatment of osteoporosis during early postmenopause.
    Delaney MF
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S12-23. PubMed ID: 16448872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.